Frank Gerola's BMF Targets SELLAS Life Sciences $3 Billion Valuation: Biotech's 'Most Expensive Coin Flip'
Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.
A person who bets that a stock will go down says SELLAS is worth way less than the market thinks it is right now. When someone disagrees this much about what a company is worth, it's a sign to watch the company's real results carefully.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.